Abpro Holdings, Inc.

Abpro Holdings, Inc. (Nasdaq: ABP) is a clinical-stage biopharmaceutical company focused on the discovery and development of bispecific antibody-based therapeutics, with a primary emphasis on oncology indications. The company entered the public markets through a SPAC business combination and, as of its Form 10-Q filed May 22, 2023, remains an active post-merger reporting company operating in the biotechnology sector. Abpro is advancing a pipeline of engineered antibody candidates designed to engage multiple disease targets simultaneously. For full deal history, sponsor details, financial filings, and pipeline tracking on Abpro Holdings and thousands of other SPAC and de-SPAC companies, sign up for complete data access at SpacDesk.